In breast cancer, identification of PIK3CA mutations informs treatment with the PI3Kα-specific inhibitor alpelisib in combination with fulvestrant as a second-line therapy for advanced disease [14,15]. This evidence concerns the gene PIK3CA and breast carcinoma.